Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (81-90 of 222) with videos related to

Pageof 23
Sort By:
Science Advances|March 26, 2025
Proteogenomic discovery of <i>RB1</i>-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targetsJacopo Iacovacci, Rachel Brough, Fatemeh Ahmadi Moughari, et al.
The Journal of Pathology|March 13, 2016
Overexpression of MYB drives proliferation of CYLD-defective cylindroma cellsNeil Rajan, Mattias K Andersson, Naomi Sinclair, et al.
Nature|February 12, 2008
Resistance to therapy caused by intragenic deletion in BRCA2Stacey L Edwards, Rachel Brough, Christopher J Lord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2013
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiencyYuqiao Shen, Farah L Rehman, Ying Feng, et al.
British Journal of Cancer|April 10, 2024
Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancerJohn Alexander, Koen Schipper, Sarah Nash, et al.
Molecular Cancer Therapeutics|July 26, 2013
Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphataseTodd R Mereniuk, Mohamed A M El Gendy, Ana M Mendes-Pereira, et al.
Cancer Cell|March 16, 2010
DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1Sarah A Martin, Nuala McCabe, Michelle Mullarkey, et al.
Molecular Cancer Therapeutics|October 12, 2018
A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted TherapeuticsJelmar Quist, Hasan Mirza, Maggie C U Cheang, et al.
Oncotarget|June 2, 2015
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathwayAnnalisa Conti, Maria Teresa Majorini, Richard Elliott, et al.
Cancer Cell|February 5, 2008
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancerElizabeth Iorns, Nicholas C Turner, Richard Elliott, et al.
Pageof 23

Showing results (81-90 of 222) with videos related to

Sort By:
Pageof 23
Science Advances|March 26, 2025
Proteogenomic discovery of <i>RB1</i>-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targetsJacopo Iacovacci, Rachel Brough, Fatemeh Ahmadi Moughari, et al.
The Journal of Pathology|March 13, 2016
Overexpression of MYB drives proliferation of CYLD-defective cylindroma cellsNeil Rajan, Mattias K Andersson, Naomi Sinclair, et al.
Nature|February 12, 2008
Resistance to therapy caused by intragenic deletion in BRCA2Stacey L Edwards, Rachel Brough, Christopher J Lord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2013
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiencyYuqiao Shen, Farah L Rehman, Ying Feng, et al.
British Journal of Cancer|April 10, 2024
Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancerJohn Alexander, Koen Schipper, Sarah Nash, et al.
Molecular Cancer Therapeutics|July 26, 2013
Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphataseTodd R Mereniuk, Mohamed A M El Gendy, Ana M Mendes-Pereira, et al.
Cancer Cell|March 16, 2010
DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1Sarah A Martin, Nuala McCabe, Michelle Mullarkey, et al.
Molecular Cancer Therapeutics|October 12, 2018
A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted TherapeuticsJelmar Quist, Hasan Mirza, Maggie C U Cheang, et al.
Oncotarget|June 2, 2015
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathwayAnnalisa Conti, Maria Teresa Majorini, Richard Elliott, et al.
Cancer Cell|February 5, 2008
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancerElizabeth Iorns, Nicholas C Turner, Richard Elliott, et al.
Pageof 23